Oxurion NV (0G99.L)
| Chiusura precedente | 0,0182 |
| Aperto | 0,0174 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,0166 - 0,0178 |
| Intervallo di 52 settimane | 0,0166 - 0,0178 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 6.516 |
| Beta (5 anni mensile) | 0,31 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,7590 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA Negma Group Investment Ltd. has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increase. This is part of Negma Group Investment Ltd.’s EUR 15 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion. Leuven, BELGIUM, Boston,
- GlobeNewswire
Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program
Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program Leuven, BELGIUM, Boston, MA, US – January 26, 2023 8:00 am CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has entered into an amendment of its mandatory convertible bonds issuance and subscription agreement with the Negma Group on January 25, 2023 (“funding prog
- GlobeNewswire
Oxurion Announces Second Amendment to Negma Funding Program
Oxurion Announces Second Amendment to Negma Funding Program Leuven, BELGIUM, Boston, MA, US – January 25, 2023 8:30 am – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that it has further amended its mandatory convertible bonds issuance and subscription agreement with the Negma Group (“funding program”). Since the start of the funding progr
